Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.
Resistance to apoptosis (programmed cell death) is a characteristic feature of human malignancies including pancreatic cancer, which is one of the leading causes of cancer deaths in the western world. Defects in this intrinsic cell death program can contribute to the multistep process of tumorigenesis, because too little cell death can disturb tissue homeostasis. Further, blockade of apoptosis pathways can cause treatment failure, because intact apoptosis signalling cascades largely mediate therapy-induced cytotoxicity. The elucidation of apoptosis pathways in pancreatic carcinoma over the last decade has resulted in the identification of various molecular defects. How apoptosis pathways can be exploited for the treatment of pancreatic cancer will be discussed in this review.
Fulda
Simone
S
University Children's Hospital, Eythstr., Ulm, Germany. simone.fulda@uniklinik-ulm.de
D000818:Animals; D017209:Apoptosis; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D008928:Mitochondria / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D053218:Receptors, Death Domain / Q000378:metabolism
D051034:Inhibitor of Apoptosis Proteins; D053218:Receptors, Death Domain